Recent developments in antiretroviral therapies

[1] Amprenavir [J]. DRUGS, 1998, 55 (06) : 837 - 842

[2] ARASTECH K, 1999, 39 ICAAC

[3] A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) : 5698 - 5703

[4] Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) : 1250 - 1255

[5] BABA M, 1999, 39 ICAAC

[6] BABA M, 1999, 12 ICAR

[7] In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors [J]. AIDS, 2000, 14 (01) : 101 - 102

[8] Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1999, 17 : 657 - 700

[9] Resistance to human immunodeficiency virus type 1 protease inhibitors [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) : 2775 - 2783

[10] New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors:: Candidates for clinical development [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (18) : 3387 - 3401

[1] Amprenavir [J]. DRUGS, 1998, 55 (06) : 837 - 842

[2] ARASTECH K, 1999, 39 ICAAC

[3] A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) : 5698 - 5703

[4] Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) : 1250 - 1255

[5] BABA M, 1999, 39 ICAAC

[6] BABA M, 1999, 12 ICAR

[7] In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors [J]. AIDS, 2000, 14 (01) : 101 - 102

[8] Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1999, 17 : 657 - 700

[9] Resistance to human immunodeficiency virus type 1 protease inhibitors [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) : 2775 - 2783

[10] New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors:: Candidates for clinical development [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (18) : 3387 - 3401